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ABSTRACT
The noradrenergic agents propranolol, and to a lesser extent,
clonidine, are used in an experimental setting to reduce switching
and anxiety in dissociative disorder patients, making them better
candidatesforpsychotherapy. Therationalefor this non-FDA-approved
use of the drugs is founded in theJames-Lange and Cannon-Bard
theories of emotion. It is hypothesized further that the mechanisms
proposed by the two theories are reinforcing of one another via
classical conditioningin theproduction and reinforcement ofchronic,
severe anxiety responses. The eJfect ofpropranolol and clonidine can
complement the eJfect of benzodiazepines in these patients. In the
experimentalprotocoldescribed, propranololorclonidine is sometimes
used at ultrahigh doses, with patients always under close medical
supervision.
INTRODUCTION
Racing, fragmented, disordered thoughtprocesses and/
or rapid switching are commonly encountered features of
Dissociative Disorder OS (DD NOS), and of multiple per-
sonality disorder (MPD) in particular. Effective psychother-
apy is difficult to accomplish in these patients when their
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thought processes are so disarrayed. Psychopharmacology
alone is not the answer to this problem, but psychoactive
medication can be successfully used to reduce ancillary
symptoms such as depression, anxiety, rapid switching, and
sleeplessness. Medication serves as an adjunctive aid to
facilitate psychotherapy. Two drugs, propranolol and cloni-
dine, have been particularly effective to help in the treat-
ment of anxiety, impulse discontrol, and rapid switching.
Propranolol is a competitive beta-adrenergic receptor
blocker that is used primarily as an anti-hypertensive agent
and for migraine headaches. Clinical observation and ex-
peri-mentation over several years have indicated that pro-
pranolol offers a very useful pharmacologic approach to
help control rapid switching in MPD patients. Other drugs
may be useful in supplementing or complementing pro-
pranolol's action, but in my experience, propranolol in large
to ultra-large doses appears to be the agent of choice. Over
a five-and one-half year period, I have conducted an open
trial of propranolol (without a control group) with more
than 100 severely incapacitated dissociative disorder pa-
tien ts. These patients were on an average regimen of800 mg
ofpropranolol per day, ranging from approximately 300 mg
to an extreme of 1600 mg per day. The longest duration of
propranolol usage was four and one-halfyears. This patient
and two others who received 1200 mg or more per day are
currently off propranolol and all other medications. They
have been functioning well for approximately one year.
The propranolol and clonidine regimens discussed in
this paper describe the use ofFDA-approved medications for
non-FDA-approved purposes at higher than FDA-approved
doses. Informed consent mustbe obtained from patients and
appropriate notations must be made in patients' charts,
including an indication that the patient understands and
gives consent. Even more important than consent is a thor-
ough knowledge of the medication and its pharmacokinet-
ics, and the close monitoring of the patient's vital signs and
the medication's side effects.
lllSTORY AND RATIONALE
Benzodiazepines were previously the agents most suc-
cessfullyused to calm thought processes and decrease switch-
ing in MPD patients at the Dissociative Disorders Program,
Rush-Presbyterian-St. Luke's Medical Center, Chicago. The
most commonly used agent, which also appeared to give the
best results, was the benzodiazepine alprazolam, character-
ized by its dose-related central nervous system activity. At
high dosage levels of alprazolam, results were satisfactory in
DISSOCLUIO:'i. Vol. III, 1\0. 3: September 1990
many patients, but stUl were not as consistent or as good as I
had hoped to see.
The use of propranolol and clonidine in patients with
post-traumatic stress disorder (PTSD) was brought to myat-
tention by an article on this subject by Kolb, Burris, and
Griffiths (1984). Although the authors found these drugs to
be somewhat useful at the doses up to 160 mg ofpropranolol
or 0.4 mg ofclonidine per day, the results were not promising
enough to encourage them to pursue intensive research.
However, the idea of using a beta-adrenergic blocker or an
alpha2-adrenergic agonist for MPD was intriguing. I had been
looking for a medication regime that would improve upon
the results from benzodiazepines. Theoretically, the use of
these medications made sense within the context of a hy-
pothesis which combined concepts from the Cannon-Bard
(1927) and James-Lange (1934) theories of emotion with
concepts from Pavlovian condi tioning (Pavlov, 1927).
The Cannon-Bard theory of emotion (1927) states, in
essence, that one feels anxious as a result ofanxiety-producing
thoughts. The physiologic result of these thoughts are
increased ventilation, tremulousness, muscle tightening, in-
creased heart rate, etc. This concept proposes that our
emotions start centrally (thought) and are followed by pe-
ripheral (physiologic) effects.
TheJames-Lange theory ofemotion (1934) reverses this
concept by proposing that physiologic symptoms are inter-
preted by the brain as anxiety or fear. For example, if one is
walking down a flight of stairs and trips, there is no time to
thinkabout the danger. Instead, one reacts reflexively, catches
him/herself, then feels tremulous with a pounding heart,
etc., which is interpreted as anxiety or fear.
The Cannon-Bard (C-B) andJames-Lange (J-L) theories
of emotion interact with one another in mutually reinforc-
ing ways. Either mechanism can initiate anxiety. Triggering
anxiety centrally via associations and/or environmental
stimuli (C-B) activates peripheral tremulousness, tachycar-
dia, etc. These physiologic symptoms foster the central
recognition ofanxiety and further exacerbate the peripheral
symptoms, creating a circularly escalating anxiety. Peripher-
al (J-L) activation by exercise or an environmental stimulus
can be so subtle as not to be recognized and brought to
consciousness, although the brain recognizes the peripheral
symptoms and often perceives them as anxiety.
Using concepts from Pavlovian conditioning one can
understand how a patient suffering from chronic anxiety can
spiral into even greater anxiety (see Figure 1). For example,
a child who was repeatedly abused in a yellow room responds
to a yellow room with tachycardia. The color, as it appeared
on the walls during the abusive episodes, was at first a neutral
stimulus (NS). With repeated episodes the neutral stimulus
becomes associated with abuse, the unconditioned stimulus
(DCS). Over time, the color seen in other environments
becomes the conditioned stimulus (CS), the cue which trig-
gers anxious thoughts able to elicit tachycardia, the condi-
tioned response (CR) without the child abuse. This is, in
essence, a Pavlovian description of the Cannon-Bard theory.
Using a similar Pavlovian approach to the James-Lange
theory, the color yellow is responded to with tachycardia
which serves as the conditioned stimulus to activate thoughts
of anxiety. Thus, it is apparent that these two systems mutu-
ally reinforce one another.
This circularity of classically reinforced anxiety would
appear to explain why the use ofbenzodiazepines alone were
insufficient to break the fear / anxiety cycle in our chronically,
severely anxious patients. Benzodiazepines work in the brain
as GABAagonists, decreasing anxietyby their effecton calcium
influx and membrane potential that decreases the firing of
the nerve cell. Propranolol, on the otl1er hand, diminishes
the peripheral symptoms ofanxiety, tremor and tachycardia
by decreasing the effect ofnorepinephrine post-synaptically
through competitive blocking of the beta receptors. Cloni-
dine, an alpha2-receptor agonist, acts pre-synaptically upon
the noradrenergic system. It stimulates the alpha.-adreno-
receptor to decrease the amount of norepinephrine avail-
able at the synapse, and decreases the sympathetic outflow
from the autonomic nervous system. The use ofbenzodiaz-
epines in combination with propranolol and/or clonidine
reduces anxiety via both the GABA system (Braun, in prep-
aration) and the noradrenergic system.
CHOOSING PROPRANOLOL
In experimentation with drugs and dosages, one must
always be cognizant of the unique and often unpredictable
hazards ofpharmacotherapy in MPD patients (Barkin, Braun,
& KIuft,1986; Braun, 1983; KIuft, 1984; Putnam, Guroff,
Silberman, Barban, & Post, 1986; Putnam, 1989). An individ-
ual patient's alters may have different responses to the same
medication. In using an experimental therapy in MPD
patients, it is essential to obtain informed consent before
therapy is initiated (Braun, 1984; Putnam, 1984; Braun,
1986). This may require explaining everything more than
once. Further-more, in MPD patients as a group, side effects
appear to be less clearly dose-related than other psychiatric
patients (Putnam, 1989).
Kolb, et al. (1984) pointed out that either the alpha.
agonist clonidine or the beta-competitive antagonist pro=
pranolol decreases the amount or the effectiveness of
norepinephrine at the synaptic cleft, thus reducing the firing
of the next cell in line. Although initially clonidine was tried,
thinking thatitwassafer, the first few patients observed could
not tolerate its sedating side effects. Propranolol was then
attempted, and had the advantage of more rapid onset of
action over clonidine and less sedation. In addition, pro-
pranolol dosage could be titrated more closely and it had less
sedating side effects. Early patients' doses were raised quite
slowly and no effect was seen until at least 240 mg was
reached. With experience, a more rapid regimen was de-
veloped, as discussed below.
Propranolol is a synthetic beta-adrenergic receptor com-
petitive blocking agent with no other autonomic nervous
system activity. Because there is no simple correlation be-
tween dose and therapeutic effect, the adjustment ofclinical-
ly effective dose requires titration. A wide dose-sensitivity
range is observed in clinical use of propranolol for manage-
ment of hypertension and other FDA-approved indications.
This is also true ofits use to control symptoms offragmented,
disordered thoughts and rapid switching in the MPD patient.
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FIGURE 1
The interaction of the James-Lange (J - L) and
Cannon-Bard (C - B) theories of emotion via
Pavlovian/Classical Conditioning (PICC) to
percipitate, reinforce and maintain bouts of
chronic severe anxiety.
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The neuropsychological effects of beta-blocking agents are
not well defined or understood, but are well documented
(Gershon, Goldstein, Moss, &van Rammen, 1979; Meibach,
Cunner, Wilson, Ishiki, & Dager, 1987; Cole & Koob, 1988;
Dimsdale, Tewton, &Joist, 1989).
Propranolol's approved indications include the manage-
ment of hypertension, long-term management of angina
pectoris, reduction of mortality after myocardial infarction,
prophylaxis of migraine, and management of essential or
familial tremor.
For dissociative disorder patients, in our experience, the
indication for the use ofpropranolol is rapid for uncon trolled
switching. Switching is usually precipitated by severe anxiety,
fear, various environmental stimuli, or their interactions
with the patient's life experiences.
Another advantage of propranolol is that its use often
reduces the amount of benzodiazepines needed, and
therefore reduces their potential to disinhibit and unleash
violen t behavior. A related advantage is propranolol's ability
(at significant doses) to inhibit impulsive behavior.
The drug's contraindications include situations where
sympathetic stimulation is required and vital - e.g.,
(1) bronchial asthma, (2) sinus bradycardia, (3) greater than
first degree heart block, (4) congestive heart failure, (5)
insulin-dependent diabetes, and (6) Raynaud's disease. Any
suggestion of bronchial asthma in a patient is an indication
for pulmonary function testing prior to administration of
propranolol. Work presented by Khan and Braun (1989)
suggests why propranolol has had good success in MPD
patients previously diagnosed as having asthma. Itwas found
that these patients had an upper airway disorder thatappeared
to be asthma, but was not.
Propranolol is known to mask hyperthyroidism, and to
change thyroid function tests, especially for the breakdown
of T 4 and T3. My colleagues and I have seen one patient in
whom propranolol therapy caused an apparent hypothyroid
condition over a six-week period. When admitted to another
hospital the T3 and T 4 tests were at upper limits of normal;
after a six-week course of propranolol, T 3was at lower limits
of normal and T 4 and TSH were normal.
Attempts were made to mimic the effects ofpropranolol
on symptoms with the cardioselective beta) blocker atenolol
with a very limited success. Atenolol, unlike propranolol,
does not penetrate the blood-brain barrier. At higher doses
propranolol appears to have both peripheral and central
effects, and the central effects appear to involve the locus
ceruleus, the lymbic system, and perhaps the frontal lobe.
Thus, use of a drug that crosses the blood-brain barrier is
probably essential for the best results.
Another attempted modification was the use of meto-
prolol a beta1-antagonist, which has effect on peripheral
target symptoms but does not greatly effect the respiratory
system. Though itis believed that 50 mg ofmetoprolol equals
80 mg of propranolol, comparable doses of metoprolol to
propranolol appear to be somewhat less effective in con-
trolling psychological symptoms such as rapid switching. In
addition, it appears that in doses greater than 200 mg/d
metoprolol it loses its beta1-selectivity. However, there are
times when metoprolol is indicated: I am currently treating
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an eight-year-old boy with 150 mg/d of metoprolol after his
original good response to propranolol was complicated by
respiratory problems.
C~DO~GEMANAG~
The obtaining of informed consent for the use of pro-
pranolol in the pharmacotherapy of dissociative disorder
patients is mandatory. For example, the patient is told thats/
he will receive an FDA-approved medication for a non-
approved use (to decrease dissociative episodes) in excess
FDA-approved dosages. It is then explained that, in the
experience ofour unit, propranolol decreases the rapidity of
the switching process, but does not prevent switching. Thus,
a person who switches less frequently is more in control, and
is better able to engage in psychotherapy. One of the major
listed side effects of propranolol is the slowing of thought
processes. This, however, is the effect that is being sought out
in our usage. The effect oflowering of blood pressure is, in
my opinion, the major side effect in the use of propranolol
described here. This side effect, depression, and others
described in the Physician's Desk Reference (PDR) (1990) and
elsewhere require careful monitoring and are explained to
the patient. Mter discussing the advantages, risks and side
effects, a notation is made of this discussion in the patient's
chart, making certain to add that the patient was competent,
understood the information s/he received, and concurred
with the decision to administer the medication. Of course,
one can only make such an entry if one is certain that this is
true. The patient must be strongly admonished against
rapidly discontinuing this medication, and warned that rap-
id discontinuance is associated with risk ofcardiac arrythmias
and a hypertensive rebound.
On the Dissociative Disorders Unit at Rush North Shore
Medical Center, orthostatic (sitting and standing) blood
pressure and pulse readings are taken before every dose of
propranolol or clonidine. A dosing schedule is instituted
after baseline blood pressure and pulse are obtained. These
are used to establish parameters for withholding propranolol.
Propranolol is withheld ifblood pressure or pulse go below
the parameters. For outpatients the parameters are set higher
and dosage increase is undertaken at a maximum ofone-half
of the inpatient rate. An inpatient is usually started on
propranolol at a dose of 10 mg four times a day. The aim is
to administer a total daily dose of40 mg to the patient on the
first day. If the first dose is given in late afternoon, I give two
20 mg doses to meet the 40 mg first-day schedule. Also, a 10
mg dose of propranolol Q3-4 hrs pm may be useful.
On the following day, our experience indicates that total
dosage may be increased to 80 mg (20 mg q.i.d.). On the
third and successive days, doses are increased by 10 mg q.i.d.
(40 mg/day) un til the total daily dosage reaches 600 mg (see
below). If the blood pressure and pulse are well above
parameters the inpatient rate of dose increase can be in-
creased slightly faster, based on the amountofpm medication
taken. In our experimental protocol we add 40 mg to the
total (regular and p.r.n) dose received the previous day, (as
10 mg q.i.d.) when more rapid increases are needed to help
control a very difficult patient.
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At the 600 mg-per-day level, dosage is increased by 10 to
20 mg per dose at a rate of 40-60 mg per day until the total
daily dosage reaches about 800 mg. Mterwards, the dosage is
increased by 60-80 mg per day, at 10 to 20 mg per dose. This
increase is pharmacologically justifiable because the in-
crease is only 10% or less of total daily dose. Preliminary
studies are underway to define effective blood levels.
In our protocol the medication is given provided that
anyone of the following parameters is not exceeded. Others
wishing to use such regimens should work in consultation
with an internist and establish parameters consistent with
the medical assessment of each unique patient.
(1) Blood pressure falls below acceptable levels (a
decrease of 20mm Hg or more systolic and 12mm Hg or
more diastolic from baseline). In a patient whose BP is nor-
mally about 100/70, a drop to about 80/60 can be tolerated;
if the normal pressure is about 90/60, a safe parameter seems
to be 78/55. At levels below these, medication is held or
withdrawn at an appropriate rate.
(2) Pulse rate falls below acceptable levels, a maximum
of20 beats per minute from baseline for the first parameter
established. This can be adjusted downward over time. In a
patient whose pulse rate is normally about 76, a pulse of 56
is usually well tolerated; after a patient has been on pro-
pranolol for a time, one may accept a pulse rate of 52.
(3) Orthostasis is seen as represented by a systolic drop
of more than 20 points, a diastolic drop of more than 10 to
15 points, and/or the pulse increasing by more than 20 beats
per minute, when the pressures/pulse are taken sitting and
then standing.
Several patients have been on sustained daily doses as
high as 1200 mg to 1600 mg/d plus p.r.n. medications.
Exercise tolerance is somewhat limited, but sexual perfor-
mance has not generally been as limited as one might
presume. One female patient engaged regularly in sex with
her husband while she was receiving 1200 mg ofpropranolol
daily, and a male patient on 1400 mg per day has reported no
sexual problems.
Increases in dose are continued in our experience until
one of the following two events is seen: (1) Switching is
decreased to a level where the patient is calmer and better
able to engage in psychotherapy. (2) Parameters are re-
peatedly exceeded. Then one can hold the last safe level, and
after one week sligh tly lower the parameters to an absolute
low ofa systolic BP of76, diastolic blood pressure of52, pulse
52.
At higher doses of propranolol, above 400 mg per day,
substitution of the longer acting form of the drug smooths
out blood-level fluctuations and adds safety against arrhyth-
mias if one or two doses are missed. For a patient receiving
400 mg of regular propranolol per day, this substitution
would result in a daily dosage of80 mg and 20 mg of regular
propranolol q.i.d. At ultra-high doses, we give 160 mg or
more oflong-acting propranolol four or five times daily, and
regular propranolol on the same schedule. Patients who
usually report problems with nightmares have had fewer
night problems at higher doses ofpropranolol. (Clonazepam
is also effective in reducing nightmares [Braun, in prepara-
tion].)
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Propranolol is given pm in doses ofapproximately 10%
or less of the total daily dose, as frequently as Q2h, since its
half life is three hours. It can be, and often is, given in
conjunction with a short-acting benzodiazepine. Patients
generally report a synergistic effect.
Depression is an occasional side effect that requires
careful assessment, and can be an additional indication to
stop administration ofthe drug. When depression is observed
during the propranolol regimen, the physician must ask:
(1) Is the depression a direct side effect of propranolol?
(2) Or, has propranolol "slowed" the patient's thoughts
to the point where s/he is recovering depressing memories
- e.g., of repeated childhood rape?
All inpatients are trained to take their own blood
pressure and pulse prior to discharge, and are asked to follow
the same regimen as do those that start the medication as
outpatients. Our experience indicates that the need for
propranolol decreases when the patient goes home.
In our experience, the two clear failures and one possi-
ble failure ofpropranolol therapy due to depression occurred
when daily doses were at 240 mg or less.
Propranolol can be given on an outpatientbasis provided
the patient has the ability to understand and follow the
physician's instructions and has continued full understanding
of informed consent. I generally prescribe at dosage level
and rate about half that of the inpatient schedule.
The outpatient must be trustworthy in drug compliance,
must learn how to take and record his or her blood pressure
and pulse before every dose of propranolol, and must keep
a daily written log of orthostatic blood pressure, pulse and
psychological-state to discuss with tl1e physician. The patient
must understand that propranolol cannot be abruptly dis-
continued without advice from the physician.
REDUCTION OF PROPRANOLOL
Medication may need to be withdrawn when there is a
significant risk to the patient because of non-cooperative
alters who may overdose or abruptly discontinue the medi-
cation. The rapid discontinuation of propranolol would
represent a risk to the patient because of its association with
cardiac arrhythmias.
The reduction ofpropranolol is accomplished gradually
under our protocol, depending on the medical circumstances
and the ability to monitor the patient's responses. Reduction
may need to be done in an inpatient setting when special
circumstances (such as a respiratory problem) arise while
the patient is taking propranolol. A patient whose severe
rapid switching had greatly improved on 800 mg per day of
propranolol developed a viral pneumoniawhich necessitated
the discontinuation of this drug. Due to the increased
switching and acting out behavior or unleashing by the
decrease of propranolol, rapid daily increase of clonidine
was successfully attempted with careful monitoring ofcardiac
status as the propranolol was being withdrawn.
Rapid dose reduction, but not drug cessation, may
sometimes be required when a patient goes from inpatient to
outpatient status, as in the case of a patient who became
uncoordinated when she returned to her teachingjob at her
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inpatient dose of 800 mg per day as a less volatile system of
alters took control in the school environment. Also, reduc-
tions may be required when the patient has a therapeutic
breakthrough. A similar phenomenon may be seen with
lithium when the acute manic phase passes: the dose required
at the acute manic phase may become a toxic dose when the
acute phase ends. Proprenalol and metoprolol has also been
used in conjunction with c10nidine to lower the required
dose of both.
CLONIDINE
The MPD patient who has concomitant bronchial asth-
ma generally can be given c10nidine safely, whereas pro-
pranolol is contraindicated. Clonidine, an imidazoline com-
pound, is an alpha2-adrenoreceptor agonist that lowers
availability of norepinephrine at the synapse. It also stimu-
lates alpha2-adrenoreceptors in the brain stem, causing a
reduced outflow from the central and sympathetic nervous
systems and decreased peripheral resistance, renal vascular
resistance, blood pressure and heart rate, although decrease
in heart rate is significantly less than that which occurs with
propranolol. This is one reason to combine the two medica-
tions (see below).
Thus, unlike the beta-blocking agents such as pro-
pranolol, the alpha-agonist c10nidine reduces the norepi-
nephrine available at the synapse, thereby reducing neuro-
nal firing, and has few contraindications. I have used it
effectively in over twenty patients.
Overall, c10nidine is slower in its onset of action and
somewhat less effective than propranolol in slowing the
switching process in MPD patients. Also, it has a significant
sedating effect. Clonidine is a good choice, however, when
the patient has a propranolol contraindication such as bron-
chial asthma or Raynaud's disease.
I have used c10nidine and propranolol simultaneously
in a few patients. The combined use appears to be indicated
when a high norepinephrine level is encountered in blood
or urine, i.e., high MHPG and/or catecholamine level. Also,
c10nidine can be added to the medication regimen in patien ts
who have responded to propranolol, but whose pulse rate
has fallen to, or below, parameter while blood pressure
remained above parameter. One may reduce propranolol a
bit and add c1onidine. I frequently use c10nidine in con-
junction with alprazolam, for the same reasons propranolol
is combined with alprazolam.
Informed patient consent must be obtained, as de-
scribed above for the protocol for use of propranolol.
Clonidine's FDA-approved use is primarily as an anti-hyper-
tensive. However, when it is used with MPD patients at non-
approved high doses, its use must be fully explained to and
understood by the patient and carefully followed by the
physician as described above for use of propranolol. Again,
the patient should be warned against stopping the medica-
tion suddenly.
The patient is usually started on c10nidine at the anti-
hypertensive dose of 0.1 mg, and increased by 0.1 mg every
second or third day. Formerly, I increased dose every five to
seven days. However, one patient was increased by 0.1 mg
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every day, with good results. Care is taken not to overmedi-
cate when using rapid increases, as there is a lag between
dosing and effect. Because ofc1onidine's sedating effect, the
evening dose is increased, going up to 0.2 mg, then to 0.3 mg
after several more days. The morning dose stays at 0.1 mg to
avoid excessive daytime sedation. A mid-day dose of 0.1 mg
may be added after the evening dose has reached the 0.3 mg
level.
The therapeutic (psychiatric) daily c10nidine dose is 1.0
mg to 2.0 mg in most patients. A few patients have been taken
to 3.0+ mg per day and one patient is currently taking 4.0 mg
per day. In the latter patient, the extreme dose of c10nidine
maintains a blood level of 2.6 ng/ml in the middle of the
range used to treat hypertension (0.5-3.4), indicating an
extreme variation in the metabolism of this drug. Monitor-
ing ofblood levels can be very useful, especially at high doses.
Clonidine has minimal pulse-slowing effect, but ortho-
static pulse as well as BP is taken and recorded before each
dose of medication is given as a safety precaution. Parame-
ters are used to monitor medications as described above.
Several patients had to be removed from c10nidine because
of oversedation.
SUMMARY
For theoretical reasons, propranolol and c10nidine were
tried alone and in combination for the treatment ofanciety,
impulsivity, and switching in dissociative disorder patients,
especially those with MPD. It was found in open trial studies
that propranolol is a useful adjunct to psychotherapy in very
anxious and/or rapidly switching dissociative disorder pa-
tients when used in our experimental protocol. It is used in
quite high dosage and under close medical supervision. It is
preferable to initiate its use on an inpatient basis, but it has
been administered successfully, albeit much more slowly, on
an outpatient basis. The long-acting form of propranolol
seems to be of value when using higher doses. These drugs
can complement benzodiazepines in these patients and
their effect has been reported to be synergistic.
Clonidine is ofvalue for the same indications, especially
in patients who cannot take propranolol. It can be used in
conjunction with propranolol if indicated.
It must be reasserted that the use ofmedication reported
in this paper is experimental and represents the open trial
experiences of the author. Physicians wishing to undertake
this approach should do so with great caution, after studying
the literature on the medication, obtaining informed consent
and closely supervising the patient and his/her physiologic
responses.•
REFERENCES
Bard, P. (1934). The neuralhormonal basis ofemotional reactions. In
C.A. Murchison (Ed.) ,Handbook ofgeneral experimentalpsychology. Wor-
cester, Massachusetts: Clark University Press.
Barkin, R., Braun, B.G., & Kluft, R.P. (1986). The dilemma of drug
treatment for multiple personality disorder patients. In B.G. Braun
(Ed.), The treatment ofmultiple personality disorder (pp. 109-132). Wash-
ington, DC: American Psychiatric Press.
149
DISSOCLUIOt\, Vol. III, 1'\0. 3: September 1990
UNUSUAL MEDICATION - MPD
Braun, B.G. (1983). Psychophysiologic phenomena in multiple
personality and hypnosis. AmericanJournal ofClinical Hypnosis, 26, 84-
92.
Braun, B.G. (1984). Uses of hypnosis with multiple personality.
Psychiatric Annals, 14, 34-40.
Braun, B.G. (1986). Issues in the psychotherapy of multiple
personality disorder. In B.G. Braun (Ed.), The treatment of multiple
personality disorder (pp. 3-28). Washington, DC: American Psychiatric
Press.
Braun, B.G. (in press). Unusual medication regimens in the therapy
of dissociative disorder patients: Benzodiazepines. DISSOCIATION.
Cannon, W.B. (1927). TheJames-Lange theoryofemotions: A critical
examination and an alternative theory. AmericanJournal ofPsychology,
39,106-124.
Cole, BJ., & Koob, G.F. (1988). Propranolol antagonizes the enhanced
condi tioned fear produced by corticotropin releasing factor. Journal
ofPharmacology and Experimental Therapeutics, 247(3), 902-910.
Dimsdale, J.E., Newton, R.P., Joist, T. (1989). Neuropsychological
side effects ofbeta-blockers. Archives ofInternal Medicine, 149,514-525.
Gershon, E.S., Goldstein, R.D., Moss, Aj., & van Kammen, D.P.
(1979). Psychosiswith ordinarydoses ofpropranolol. AnnalsofIntemal
Medicine, 90, 938-939.
Khan, SA, & Braun, B.G. (1989). Pulmonary manifestations in
patients with dissociative disorders: A review of 40 consecutive cases.
Dissociative disorders: 1989: Proceedings ofthe sixth international conference
onmultiplepersonality/dissociativestates. Chicago: Rush-Presbyterian-St.
Luke's Medical Center.
Kluft, R.P. (1984). Aspects of the treatment of multiple personality
disorder. Psychiatric Annals, 14,51-55.
Kolb, L., Burris,B.C., & Griffiths, S. (1984). Propranolol and clonidine
in treatment of chronic post-traumatic stress disorders of war. In B.
van der KoIk (Ed.) ,Post-traumaticstress disorder: Psychologicaland biologic
sequelae. Washington, DC: American Psychiatric Press.
Meibach, R.C., Dunner, D., Wilson, L.G., Ishiki, D., & Dager, S.R.
(1987). Comparative efficacy of propranolol, chlordiazepoxide,
and placebo in the treatment of anxiety: a double-blind trial.Journal
of Clinical Psychiatry, 48, 355-358.
Pavlov, J.P. (1987). Conditioned reflexes. New York: Oxford University
Press.
Physician's Desk Reference (44th ed). (1990). Oradell, J: Medical
Economics Co.
Putnam, F.W. (1984). The study of multiple personality disorder:
General strategies and practical considerations. PsychiatricAnnals, 14,
58-62.
Putnam, F.W. (1989). Diagnosis and treatment of multiple personality
disorder. 1 ew York: Guilford Press.
Putnam, F.W., Guroff,Jj., Silberman, EX, Barban, L., & Post, R.M.
(1986). The clinical phenomenologyofmultiple personalitydisorder:
A review of 100 recent cases.Journal ofClinical Psychiatry, 47, 285-293.
150
EDITORlALADDENDUM:
Bennett G. Braun, M.D. 's article, "Unusual Medication Regimens
in the Treatment of Dissociative Disorder Patients: Part 1.
NoradrenergicAgents, " is an important contribution to the literature
which must be placed in perspective. It describes several pioneering
efforts to establish a rational pharmacologic basis for offering relief
and comfort to dissociative disorderpatients. In afield in which little
is firmly established and clinicians are eager to help distressed
patients, thereis danger that appropriatereservations will be lrypassed
and that readers will embrace preliminary reports with uncritical
enthusiasm or desperation. It must be emphasized that the regimens
it discusses are highly experimental, and have been tested in an open
and uncontrolled manner in a specialized inpatient setting with
skilled and readily-available medical consultation and back-up.
Theirsuitabilityfor use in othersettings and theirgeneral applicability
remains to be assessed, and cannot be assumed to be established.
Those who would seek to replicate such interventions must bear in
mind that the applications described are experimental and notFDA
approved. Genuine informed consent and medical assessment,
clearance, and ongoingfollow-up are essential, and consultation is
advised before proceeding.
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